[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"NovoCure Ltd.\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":66},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,41],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":26,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100480655","ttfields-in-general-routine-clinical-care-in-patients-with-pleural-mesothelioma-study-100480655",false,"NCT05538806","TTFields in General Routine Clinical Care in Patients With Pleural Mesothelioma Study","TTFields in General Routine Clinical Care in Patients With Pleural Mesothelioma Study - TIGER Meso Study","TIGER Meso","Inclusion Criteria:\n\n* ≥ 18 years of age\n* Histologically confirmed pleural mesothelioma without any option of curative resection\n* Planned treatment with NovoTTF-200T System according to IFU and medical guidelines\n* Life expectancy more than 3 months at day of enrollment\n* Signed informed consent for use and processing of data\n\nExclusion Criteria:\n\n• Previous treatment with NovoTTF-200T for more than 1 week at day of enrollment","ALL","18 Years",{"count":20,"type":21},198,"ESTIMATED","OBSERVATIONAL","The purpose of this post-authorisation medical device study is to obtain real life data on the use of Tumor Treating Fields (TTFields) in patients with pleural mesothelioma in routine clinical care. Patients with pleural mesothelioma and clinical indication for TTFields treatment will be enrolled in the study after signing Informed consent to use their data and process it centrally for research purposes. The clinical indication for TTFields is one of the inclusion criteria and is defined prior to inclusion by the treating physician.",[25],"Pleural Mesothelioma",[25,27],"TTFields","RECRUITING","2025-08-18",{"date":31,"type":32},"2025-08-22","ACTUAL",{"date":34,"type":32},"2023-08-01",{"date":36,"type":21},"2028-06",{"name":38,"class":39},"NovoCure Ltd.","INDUSTRY",23,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":47,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":49,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":51,"conditions":52,"keywords":54,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":57,"lastUpdatePostDateStruct":58,"startDateStruct":60,"completionDateStruct":62,"leadSponsor":64,"locationsCount":65},"100587108","ttfields-general-routine-clinical-care-in-ndgbm-patients-a-french-prospective-non-interventional-study-tiger-france-100587108","NCT06924099","TTFields General Routine Clinical Care in ndGBM Patients: a French Prospective Non-Interventional Study (TIGER France)","Tumor Treating Fields General Routine Clinical Care in Newly Diagnosed Glioblastoma Patients: a French Prospective Non-Interventional Study - TIGER France","TIGER France","Inclusion Criteria:\n\n* Participant aged ≥ 18 years old.\n* Participant with newly diagnosed GBM.\n* Participant who completed radiochemotherapy after surgery or biopsy.\n* Participant within first 2 cycles of maintenance TMZ.\n* Participant for whom the physician has decided to initiate treatment with Optune® according to Instruction For Use or medical guidelines.\n\nExclusion Criteria:\n\n* Participant currently participating in a prospective clinical trial studying a different treatment than the one studied in this current prospective study.\n* Patient currently breastfeeding.\n* Patient who is pregnant, thinks she might be pregnant or is trying to become pregnant. Patient of childbearing potential must use a contraceptive method for the whole duration of their participation in the study.\n* Patient suffering from a significant neurological disease (primary epilepsy, dementia, progressive degenerative neurological disorder, meningitis or encephalitis, hydrocephalus associated with increased intracranial pressure).\n* Patient with a known sensitivity to conductive hydrogels, such as gel used with electrocardiogram (ECG) or transcutaneous electrical nerve stimulation (TENS) electrodes.\n* Patient with an active implanted medical device, a cranial defect (such as a missing bone that has not been replaced) or bullet fragments. Active electronic devices include, for example, deep brain stimulators, spinal cord stimulators, vagus nerve stimulators, pacemakers and defibrillators.\n* Participant being deprived of liberty by a judicial or administrative decision, or who is under a measure of legal protection (e.g. guardianship or curatorship).",{"count":50,"type":21},430,"This prospective multicenter non-interventional study (NIS) aims at confirming the survival benefit of Optune Gio® - in terms of OS and PFS - and describing device usage (compliance will be measured through patient's usage report, recorded by each device) and impact on QoL, in a real-life setting in France, in a large cohort of participants with newly diagnosed GBM who completed radiotherapy and concomitant TMZ after surgery and initiatingtreatment with Optune Gio® device together with maintenance TMZ.\n\nA special emphasis will be given to the evaluation of QoL and the impact of Optune Gio® on daily life, considering the limited life expectancy of these patients, the symptom burden and significant disease-related disability.",[53],"Glioblastoma",[55,56],"newly diagnosed Glioblastoma (GBM)","Tumor Treating Fields - TTFields","2025-04-04",{"date":59,"type":32},"2025-04-11",{"date":61,"type":32},"2024-01-11",{"date":63,"type":21},"2029-01-31",{"name":38,"class":39},24,""]